Bernard M Fine

US Patent:

20090239214, Sep 24, 2009

Filed:

Aug 1, 2005

Appl. No.:

11/658605

Inventors:

Hongyue Dai - Kenmore WA, US
Yudong He - Kirkland WA, US
Mao Mao - Redmond WA, US
Bernard Fine - Menlo Park CA, US
Laura J. van't Veer - Amsterdam, NL
Marc J. van de Vijver - Amsterdam, NL

International Classification:

C12Q 1/68
G06F 19/00

US Classification:

435 6, 702 19

Abstract:

The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein.

US Patent:

20090247549, Oct 1, 2009

Filed:

May 20, 2008

Appl. No.:

12/154087

Inventors:

Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
Bernard Fine - Menlo Park CA, US

International Classification:

A61K 31/497
A61P 35/00

US Classification:

51425505

Abstract:

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

US Patent:

20070197473, Aug 23, 2007

Filed:

Nov 3, 2006

Appl. No.:

11/592528

Inventors:

Stanley Frankel - Yardley PA, US
Paul Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US
Bernard Fine - Menlo Park CA, US

International Classification:

A61K 31/69
A61K 31/19

US Classification:

514064000, 514575000

Abstract:

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.